SCHEMBL2597682

SCHEMBL2597682

CN1C(=O)c2ccccc2C1C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.53
KDM4E B2RXH2 3/20 0.53
CYP1A2 P05177 2/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
CYP3A4 P08684 1/20 0.53
HTT P42858 2/20 0.51
FFAR1 O14842 2/20 0.51
LMNA P02545 2/20 0.51
POLB P06746 3/20 0.50
MAPT P10636 2/20 0.50
CYP2C9 P11712 1/20 0.50
P2RX7 Q99572 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.48
HPGD P15428 1/20 0.44
EDNRB P24530 1/20 0.43
EDNRA P25101 1/20 0.43
GAA P10253 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7703878 0.81 GPR3 (0.56) ALDH1A1KDM4EMEN1KMT2AHTT
SCHEMBL1888409 0.78 FFAR1 (0.54) ALDH1A1MEN1KMT2AHTTFFAR1
SCHEMBL14790130 0.78 ALDH1A1 (0.53) ALDH1A1KDM4ECYP1A2MEN1KMT2A
SCHEMBL12185528 0.78 HTT (0.48) ALDH1A1KDM4ECYP1A2MEN1KMT2A
SCHEMBL12202089 0.77 ALDH1A1 (0.43) ALDH1A1KDM4ECYP1A2MEN1KMT2A
SCHEMBL13206625 0.76 MEN1 (0.56) ALDH1A1KDM4ECYP1A2MEN1KMT2A
SCHEMBL22623757 0.76 MEN1 (0.56) ALDH1A1KDM4ECYP1A2MEN1KMT2A
SCHEMBL2173695 0.76 MEN1 (0.56) ALDH1A1KDM4ECYP1A2MEN1KMT2A
SCHEMBL4468979 0.75 HTT (0.48) ALDH1A1KDM4ECYP1A2MEN1KMT2A
SCHEMBL31098689 0.75 RAB9A (0.69) ALDH1A1KDM4EMEN1KMT2ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2571860-A1 2-PHENYL BENZOYLAMIDES Pfizer Inc (US) 2013-03-27 EP disclosed
US-20130072519-A1 2-PHENYL BENZOYLAMIDES CONN EDWARD LEE (US) 2013-03-21 US disclosed
US-20130072519-A1 2-PHENYL BENZOYLAMIDES CONN EDWARD LEE (US) 2013-03-21 US disclosed
US-20130072519-A1 2-PHENYL BENZOYLAMIDES CONN EDWARD LEE (US) 2013-03-21 US disclosed
WO-2011145022-A1 2-PHENYL BENZOYLAMIDES PFIZER INC. (US) 2011-11-24 WO disclosed
WO-2011145022-A1 2-PHENYL BENZOYLAMIDES PFIZER INC. (US) 2011-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072519-A1 2-PHENYL BENZOYLAMIDES APOB, MTTP, HADHB ALDH1A1 885/4885KDM4E 3018/4885CYP1A2 273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.